Search - tctmd.com

Displaying 1 - 20 of 73

Sort: Relevancy | Date

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

News Conference News TCT 2025

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

October 27, 2025

Sirolimus-Coated Balloon Meets Mark in De Novo Lesions and ISR: SELUTION

News Conference News TCT 2025

Sirolimus-Coated Balloon Meets Mark in De Novo Lesions and ISR: SELUTION

Michael O'Riordan

October 26, 2025

Medicare Analysis Reassures on PCI in Ambulatory Surgery Centers

News Conference News SCAI 2025

Medicare Analysis Reassures on PCI in Ambulatory Surgery Centers

May 07, 2025

Paclitaxel or Sirolimus: New PAD Studies Shed Light on Choices

News Conference News CX Symposium 2025

Paclitaxel or Sirolimus: New PAD Studies Shed Light on Choices

April 23, 2025

AGENT IDE: DCB Performance for In-Stent Restenosis Lasts Out to 2 Years

News Conference News CRT 2025

AGENT IDE: DCB Performance for In-Stent Restenosis Lasts Out to 2 Years

March 10, 2025

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

News Conference News VIVA 2024

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

November 05, 2024

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

News Conference News TCT 2024

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

October 29, 2024

Solid 2-Year Data With ‘Unlocking’ Coronary Stent: BIOADAPTOR RCT

News Conference News EuroPCR 2024

Solid 2-Year Data With ‘Unlocking’ Coronary Stent: BIOADAPTOR RCT

Michael O'Riordan

May 28, 2024

Stepwise DAPT De-escalation Shows Promise in DCB-Only PCI for ACS

News Conference News EuroPCR 2024

Stepwise DAPT De-escalation Shows Promise in DCB-Only PCI for ACS

Yael L. Maxwell

May 15, 2024

Mixed Bag With DCBs for In-Stent Restenosis, Small Coronary Arteries

News Conference News CRT 2024

Mixed Bag With DCBs for In-Stent Restenosis, Small Coronary Arteries

March 14, 2024

Full AGENT IDE Results Affirm Benefits of DCB for In-Stent Restenosis

News Conference News CRT 2024

Full AGENT IDE Results Affirm Benefits of DCB for In-Stent Restenosis

March 09, 2024

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

News Conference News AHA 2023

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

Michael O'Riordan

November 11, 2023

‘Light at the End of the Tunnel’ for In-Stent Restenosis: AGENT IDE Wins Big

News Conference News TCT 2023

‘Light at the End of the Tunnel’ for In-Stent Restenosis: AGENT IDE Wins Big

October 25, 2023

PROSPECT MONSTER: Real-World Data Confirm Low-Dose DCB Efficacy in PAD

News Conference News LINC 2023

PROSPECT MONSTER: Real-World Data Confirm Low-Dose DCB Efficacy in PAD

June 21, 2023

Early Data on Temporary Spur in BTK PAD Show Efficacy, Limited Recoil

News Conference News LINC 2023

Early Data on Temporary Spur in BTK PAD Show Efficacy, Limited Recoil

June 09, 2023

Meta-analysis Finds No Excess Mortality Risk With Coronary Revascularization

News Conference News EuroPCR 2023

Meta-analysis Finds No Excess Mortality Risk With Coronary Revascularization

Michael O'Riordan

May 19, 2023

Long-Awaited BEST-CLI Results Favor Surgery Over Endovascular Therapy in CLTI

News Conference News AHA 2022

Long-Awaited BEST-CLI Results Favor Surgery Over Endovascular Therapy in CLTI

November 07, 2022

SCAAR Registry Delves Into Left Main Revascularization Outcomes

News Conference News TCT 2022

SCAAR Registry Delves Into Left Main Revascularization Outcomes

Michael O'Riordan

September 19, 2022

Long-term Outcomes With PCI and CABG: More Analyses to Stir the Pot

News Conference News EuroPCR 2022

Long-term Outcomes With PCI and CABG: More Analyses to Stir the Pot

Michael O'Riordan

May 23, 2022

DISRUPT PAD III: Lithotripsy Prep Linked to Better PAD Patency at 1 Year

News Conference News SCAI 2022

DISRUPT PAD III: Lithotripsy Prep Linked to Better PAD Patency at 1 Year

May 23, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.